Literature DB >> 25941354

The regulatory role of invariant NKT cells in tumor immunity.

Rosanna M McEwen-Smith1, Mariolina Salio1, Vincenzo Cerundolo2.   

Abstract

Invariant natural killer T (iNKT) cells are a unique population of T lymphocytes, which lie at the interface between the innate and adaptive immune systems, and are important mediators of immune responses and tumor surveillance. iNKT cells recognize lipid antigens in a CD1d-dependent manner; their subsequent activation results in a rapid and specific downstream response, which enhances both innate and adaptive immunity. The capacity of iNKT cells to modify the immune microenvironment influences the ability of the host to control tumor growth, making them an important population to be harnessed in the clinic for the development of anticancer therapeutics. Indeed, the identification of strong iNKT-cell agonists, such as α-galactosylceramide (α-GalCer) and its analogues, has led to the development of synthetic lipids that have shown potential in vaccination and treatment against cancers. In this Masters of Immunology article, we discuss these latest findings and summarize the major discoveries in iNKT-cell biology, which have enabled the design of potent strategies for immune-mediated tumor destruction. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25941354      PMCID: PMC4430818          DOI: 10.1158/2326-6066.CIR-15-0062

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  164 in total

1.  Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo.

Authors:  Jelena S Bezbradica; Aleksandar K Stanic; Naoto Matsuki; Helene Bour-Jordan; Jeffrey A Bluestone; James W Thomas; Derya Unutmaz; Luc Van Kaer; Sebastian Joyce
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

2.  The crystal structure of human CD1d with and without alpha-galactosylceramide.

Authors:  Michael Koch; Victoria S Stronge; Dawn Shepherd; Stephan D Gadola; Bini Mathew; Gerd Ritter; Alan R Fersht; Gurdyal S Besra; Richard R Schmidt; E Yvonne Jones; Vincenzo Cerundolo
Journal:  Nat Immunol       Date:  2005-07-10       Impact factor: 25.606

3.  Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections.

Authors:  Jochen Mattner; Kristin L Debord; Nahed Ismail; Randal D Goff; Carlos Cantu; Dapeng Zhou; Pierre Saint-Mezard; Vivien Wang; Ying Gao; Ning Yin; Kasper Hoebe; Olaf Schneewind; David Walker; Bruce Beutler; Luc Teyton; Paul B Savage; Albert Bendelac
Journal:  Nature       Date:  2005-03-24       Impact factor: 49.962

4.  CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis.

Authors:  F Fais; C Tenca; G Cimino; V Coletti; S Zanardi; D Bagnara; D Saverino; D Zarcone; G De Rossi; E Ciccone; C E Grossi
Journal:  Leukemia       Date:  2005-04       Impact factor: 11.528

5.  Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load.

Authors:  Johan W Molling; Wendy Kölgen; Hans J J van der Vliet; Martijn F Boomsma; Hinke Kruizenga; Carolien H Smorenburg; Barbara G Molenkamp; Johannes A Langendijk; C René Leemans; B Mary E von Blomberg; Rik J Scheper; Alfons J M van den Eertwegh
Journal:  Int J Cancer       Date:  2005-08-10       Impact factor: 7.396

6.  Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells.

Authors:  L S Metelitsa; K I Weinberg; P D Emanuel; R C Seeger
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

7.  Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Authors:  David H Chang; Keren Osman; John Connolly; Anjli Kukreja; Joseph Krasovsky; Maggi Pack; Aisha Hutchinson; Matthew Geller; Nancy Liu; Rebecca Annable; Jennifer Shay; Kelly Kirchhoff; Nobusuke Nishi; Yoshitaka Ando; Kunihiko Hayashi; Hani Hassoun; Ralph M Steinman; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

8.  Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo.

Authors:  Jennifer L Matsuda; Laurent Gapin; Jody L Baron; Stéphane Sidobre; Daniel B Stetson; Markus Mohrs; Richard M Locksley; Mitchell Kronenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

9.  Cross-presentation of disialoganglioside GD3 to natural killer T cells.

Authors:  Dianna Y Wu; Neil H Segal; Stephane Sidobre; Mitchell Kronenberg; Paul B Chapman
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

10.  A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.

Authors:  Madhav V Dhodapkar; Matthew D Geller; David H Chang; Kanako Shimizu; Shin-Ichiro Fujii; Kavita M Dhodapkar; Joseph Krasovsky
Journal:  J Exp Med       Date:  2003-06-09       Impact factor: 14.307

View more
  62 in total

Review 1.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

2.  Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells.

Authors:  Chunlei Li; Baobao Song; Patricia M Santos; Lisa H Butterfield
Journal:  Cell Immunol       Date:  2018-11-01       Impact factor: 4.868

3.  Immunological characterization of a rigid α-Tn mimetic on murine iNKT and human NK cells.

Authors:  Silvia Fallarini; Alvaro Brittoli; Michele Fiore; Grazia Lombardi; Olivier Renaudet; Barbara Richichi; Cristina Nativi
Journal:  Glycoconj J       Date:  2017-06-01       Impact factor: 2.916

4.  Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Authors:  Maureen Banach; Eva-Stina Edholm; Xavier Gonzalez; Abdellatif Benraiss; Jacques Robert
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

Review 5.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

6.  Integration of Oncogenes via Sleeping Beauty as a Mouse Model of HPV16+ Oral Tumors and Immunologic Control.

Authors:  Yi-Hsin Lin; Ming-Chieh Yang; Ssu-Hsueh Tseng; Rosie Jiang; Andrew Yang; Emily Farmer; Shiwen Peng; Talia Henkle; Yung-Nien Chang; Chien-Fu Hung; T-C Wu
Journal:  Cancer Immunol Res       Date:  2018-01-23       Impact factor: 11.151

Review 7.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

8.  Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma.

Authors:  Iwona Hus; Agnieszka Bojarska-Junak; Marzena Kamińska; Aneta Dobrzyńska-Rutkowska; Karolina Szatan; Agnieszka Szymczyk; Bożena Kukiełka-Budny; Dariusz Szczepanek; Jacek Roliński
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

Review 9.  CAR-armed cell therapy for gliomas.

Authors:  You Zhai; Guanzhang Li; Tao Jiang; Wei Zhang
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

Review 10.  mTOR and its tight regulation for iNKT cell development and effector function.

Authors:  Wei Yang; Balachandra Gorentla; Xiao-Ping Zhong; Jinwook Shin
Journal:  Mol Immunol       Date:  2015-08-04       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.